Evidence map›Paper›PMID 42816645›Full record

ArticleNature methods2026

CytoVI: deep generative modeling of antibody-based single cell data.

Florian Ingelfinger, Nathan Levy, Can Ergen, Artemy Bakulin, Alexander Becker, Pierre Boyeau, Martin Kim, Diana Ditz, Jan Dirks, Jonas Maaskola and 5 more

Abstract read
In one paragraph

Article in Nature methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Florian IngelfingerDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. florian.ingelfinger@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0001-6890-9753
Nathan LevyDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Can ErgenDepartment of Electrical Engineering and Computer Science, University of California, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-3096-2927
Artemy BakulinDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Alexander BeckerDepartment of Electrical Engineering and Computer Science, University of California, Berkeley, CA, USA.
Pierre BoyeauDepartment of Electrical Engineering and Computer Science, University of California, Berkeley, CA, USA.
Martin KimDepartment of Electrical Engineering and Computer Science, University of California, Berkeley, CA, USA.ORCID http://orcid.org/0009-0000-2115-6213
Diana DitzDivision of Hematology and Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Jan DirksDivision of Hematology and Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Jonas MaaskolaDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Tobias WertheimerDepartment of Internal Medicine I, Medical Center-University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-8480-7391
Robert ZeiserDepartment of Internal Medicine I, Medical Center-University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0001-6565-3393
Corinne C WidmerDivision of Hematology and Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Ido AmitDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. ido.amit@weizmann.ac.il.ORCID http://orcid.org/0000-0003-2968-877X
Nir YosefDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. nir.yosef@weizmann.ac.il.ORCID http://orcid.org/0000-0001-9004-1225

Funding

Single-Cell Transcriptomics of Non-Activated Latently Infected T cells Isolated from HIV+ Drug UsersR61DA048444 · NIDA · J. DAVID GLADSTONE INSTITUTES · PI OTT, MELANIE MARIA · 2019 to 2021
$2.0M
Deutsche Forschungsgemeinschaft (German Research Foundation) 259373024 - TRR 167Deutsche Forschungsgemeinschaft (German Research Foundation) 441891347-P23EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 101055341-TROJAN- CellEC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 101106452; STIC-GBMEC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) MiTE, 101123436European Molecular Biology Organization (EMBO) ALTF 723-2022Israel Science Foundation (ISF) 1944/22NIDA NIH HHS R61 DA048444
6 · The paper itself

Abstract

Antibody-based single-cell technologies, such as flow cytometry, mass cytometry and CITE-seq, have become widely used in clinical diagnostics and basic research; however, their analysis is complicated by technical noise, batch effects, platform differences and restricted antibody panels. Here we present CytoVI, a probabilistic generative model for statistically rigorous unified analysis of antibody-based single-cell data. CytoVI generates informative cell embeddings, imputes missing measurements, performs differential protein expression testing and automates annotation of cells in a single probabilistic model. We applied CytoVI to build an integrated B cell maturation atlas spanning 350 proteins and identified proteins associated with immunoglobulin class-switching. In a cohort of patients with B cell non-Hodgkin lymphoma profiled by flow cytometry and CITE-seq, CytoVI uncovered disease-associated T cell states. CytoVI is available as open-source software at scvi-tools.org .

Indexed as

AntibodiesSingle-Cell AnalysisSoftwareB-LymphocytesFlow CytometryGenerative Artificial IntelligenceHumansLymphoma, B-CellAntibodies

Identifiers

PMID42816645
PMCPMC13645629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.